Dendritic cell immunotherapy in uterine cancer

Coosemans, An; Tuyaerts, Sandra; Vanderstraeten, Anke; Vergote, Ignace; Amant, Frédéric; Gool, Stefaan W. Van

doi:10.4161/hv.28716

Cited by 5 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are some data about dendritic cell vaccination [108][109][110] and about checkpoint inhibition, particularly in view of mismatch repair-deficient cancers [111]. In this phase II study, the authors examined the efficacy of pembrolizumab in several tumor types (n = 41), including two endometrial cancers.…”

Section: Endometrial Cancersmentioning

confidence: 99%

Immunotherapy in Gynecologic Cancers

Vetter¹,

Heinzelmann‐Schwarz²

2017

Immunotherapy - Myths, Reality, Ideas, Future

View full text Add to dashboard Cite

During the last years, significant progress in the understanding of signaling pathways of immune cells has revive the field of immune therapy for cancer. In this chapter, we explain the recent immunotherapy-based strategies for the treatment of gynecological cancers including cervical cancer, endometrial cancer, ovarian cancer, and vulvar cancer. This work will mainly focus on emerging clinical data on immune checkpoint inhibitors. But also data on adoptive T cell therapies and vaccines will be presented. It is anticipated that in future biomarker-guided randomized trials will provide better approaches in terms of response and resistance to immune therapy. The use of combination therapy for gynecological cancer might be one possible approach to overcome resistance.

show abstract

Section: Endometrial Cancersmentioning

confidence: 99%

Immunotherapy in Gynecologic Cancers

Vetter¹,

Heinzelmann‐Schwarz²

2017

Immunotherapy - Myths, Reality, Ideas, Future

View full text Add to dashboard Cite

show abstract

“…The clinical relevance of immunotherapy in the treatment of solid malignancies is firmly established, and checkpoint inhibitors are approved for the treatment of several solid tumors. Recently, immunotherapy has emerged as an appealing therapeutic strategy in patients with EC and may be particularly relevant in the setting of deficient MMR (dMMR) . During the evaluation of specimens from NRG Oncology/GOG210, Goodfellow and colleagues identified MSI‐H status in nearly 30% of patients .…”

mentioning

confidence: 99%

Mismatch repair in endometrioid endometrial cancer: Increasing our therapeutic proficiency by capitalizing on molecular deficiency

Eskander

2018

Cancer

View full text Add to dashboard Cite

show abstract

mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70)

Coosemans

Tuyaerts

Morias

et al. 2016

Methods in Molecular Biology

View full text Add to dashboard Cite

The immune system is a crucial player in the development of cancer. Once it is in imbalance and immunosuppressive mechanisms supporting tumor growth take over control, dendritic cell immunotherapy might offer a solution to restore the balance. There are several methods to manufacture dendritic cells but none of them has yet proven to be superior to others. In this chapter, we discuss the methodology using electroporation of mRNA encoding Wilms' tumor gene 1, survivin, and TriMix (mixture of caTLR4, CD40L, and CD70) to simultaneously load and mature dendritic cells.

show abstract

Dendritic cell immunotherapy in uterine cancer

Cited by 5 publications

References 46 publications

Immunotherapy in Gynecologic Cancers

Immunotherapy in Gynecologic Cancers

Mismatch repair in endometrioid endometrial cancer: Increasing our therapeutic proficiency by capitalizing on molecular deficiency

mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70)

Contact Info

Product

Resources

About